Next-generation mass spectrometer market seen reaching $5.75 billion by 2030

The next-generation mass spectrometer market is projected to grow from $3.6 billion in 2025 to $5.75 billion by 2030, driven by demand for higher sensitivity, AI-enabled analysis and broader use in clinical, environmental and food testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Next-generation mass spectrometers are becoming core tools for research, diagnostics and molecular analysis. - The market’s expansion signals stronger demand for higher-resolution instruments that can support personalized medicine, drug discovery and testing in regulated industries. - Growth in clinical diagnostics, forensic science, environmental monitoring and food safety testing broadens the commercial base for the technology.

What happened: - The next-generation mass spectrometer market is projected to rise from $3.6 billion in 2025 to $3.96 billion in 2026. - The market is forecast to reach $5.75 billion by 2030. - That implies a 10.1% CAGR from 2025 to 2026 and a 9.8% CAGR from 2026 to 2030. - The Business Research Company published the outlook on Aug. 19, 2026. - A free sample report is available here. - The full report is available here.

The details: - Older mass spectrometry systems, including conventional ion trap and quadrupole technologies, have limited sensitivity and resolution. - Pharmaceutical and biotech research has added to demand for next-generation systems. - High operational complexity and maintenance costs remain market challenges. - The technology often combines artificial intelligence, innovative ion optics and real-time data processing. - These systems can reduce sample requirements and improve molecular insight compared with traditional instruments. - Growth through 2030 is expected to come from advances in next-generation Fourier transform mass spectrometry, or FT-MS, and orbitrap systems. - Key trends include high-resolution mass spectrometry, real-time analytics, growth in proteomics and metabolomics, broader adoption in environmental and food testing, and instrument miniaturization. - In 2025, North America held the largest market share. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Personalized medicine is a major demand driver because it depends on detailed molecular profiling to tailor care. - Next-generation mass spectrometers support biomarker identification, treatment monitoring and custom therapy design. - A February 2024 Personalized Medicine Coalition report found the FDA authorized 16 new personalized medicines for rare diseases in 2023, up from six in 2022. - That surge points to a larger market for instruments that can support individualized treatment development and monitoring. - The forecast also reflects a shift from basic molecular detection toward faster, more automated and more data-rich workflows.

What's next: - The market is expected to keep expanding as AI integration improves data interpretation and real-time analytics. - More adoption is likely in clinical diagnostics, environmental monitoring and food safety testing as users seek higher sensitivity and faster results. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and updated graphics.

The bottom line: - Next-generation mass spectrometers are moving from specialized lab tools to broader platform technologies, and the market outlook reflects that shift.